ASX Announcement

28 March 2024

Notice Under Section 708A(5)(e) of the Corporations Act 2001

This notice is given by OncoSil Medical Limited (ASX:OSL) ('Company) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (the Corporations Act).

Type	Shares
Class/description	Ordinary
ASX code	OSL
Date of issue	28 March 2024
Number issued	281,000,000

The Company gives notice under section 708A(5)(e) of the Corporations Act that:

1. the Company issued the Shares issued without disclosure under Part 6D.2 of the Corporations Act;
2. as at the date of this notice, the Company has complied with:
   (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
   (ii) sections 674 and 674A of the Corporations Act; and
3. as at the date of this notice, there is no information to be disclosed which is 'excluded information' (as defined in sections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by the Company.

Christian Dal Cin
Company Secretary

Mr Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	Mr Christian Dal Cin CFO & Company Secretary E: c.dalcin@acclime.com T: +61 3 9824 5254	**Media & Investor Enquiries** The Capital Network Julia Maguire P: +61 2 8999 3699 E: julia@thecapitalnetwork.com.au

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival[1].

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (^{32}P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Turkey and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

1 www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/